Prevalence of “Flat-Line” Thromboelastography During Extracorporeal Membrane Oxygenation for Respiratory Failure in Adults

We evaluated the prevalence of a thromboelastography reaction time (R time) >90 min (“flat-line”) reversible with heparinase during extracorporeal membrane oxygenation (ECMO). We evaluated the association between “flat-line” thromboelastography, other coagulation tests, and risk of bleeding during ECMO. Thirty-two consecutive patients on ECMO were included. Anticoagulation was provided by continuous infusion of unfractionated heparin to maintain an activated partial thromboplastin time (aPTT) ratio between 1.5 and 2.0. Activated clotting times (ACTs) thromboelastography without and with heparinase were measured. Occurrence of bleeding was recorded. Median heparin infusion rate was 16 (12–20) IU/kg/h, aPTT ratio was 1.67 (1.48–1.96), and ACT was 173 (161–184) sec. One hundred forty-five (46%) of 316 paired thromboelastography samples were “flat lines” all reversed with heparinase. Patients with “flat-line” thromboelastography received more heparin (p = 0.001) but had similar platelet count (p = 0.164) and fibrinogen level (p = 0.952) than those without. Activated partial thromboplastin time, ACT, and R time without heparinase weakly correlated between each other (Spearman correlation ⩽0.36) with poor agreement (Cohen’s &kgr; ⩽0.10). Major bleeding occurred in seven (22%) patients. Bleeding during ECMO was not predicted by any of the used test. In conclusion, adjusting heparin infusion to maintain aPTT ratio between 1.5 and 2.0 frequently resulted in “flat-line” thromboelastography.

[1]  I. Martinelli,et al.  Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults. , 2016, Minerva anestesiologica.

[2]  G. Weigel,et al.  Extracorporeal Membrane Oxygenation Induces Short-Term Loss of High-Molecular-Weight von Willebrand Factor Multimers , 2015, Anesthesia and analgesia.

[3]  J. Ko,et al.  Evaluation of "flat-line" thromboelastography after reperfusion during liver transplantation. , 2015, Transplantation proceedings.

[4]  H. Schöchl,et al.  Trauma Bleeding Management: The Concept of Goal-Directed Primary Care , 2014, Anesthesia and analgesia.

[5]  B. Karon.  Why is everyone so excited about thromboelastrography (TEG)? , 2014, Clinica chimica acta; international journal of clinical chemistry.

[6]  R. Fiser,et al.  Unfractionated Heparin Activity Measured by Anti-Factor Xa Levels Is Associated With the Need for Extracorporeal Membrane Oxygenation Circuit/Membrane Oxygenator Change: A Retrospective Pediatric Study , 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[7]  F. Masud,et al.  Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients , 2014, Perfusion.

[8]  G. Nardi,et al.  Thromboelastometry for guiding bleeding management of the critically ill patient: a systematic review of the literature. , 2014, Minerva anestesiologica.

[9]  D. Rodriquez,et al.  Anti-Factor Xa Assay Is a Superior Correlate of Heparin Dose Than Activated Partial Thromboplastin Time or Activated Clotting Time in Pediatric Extracorporeal Membrane Oxygenation* , 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[10]  T. Nguyen,et al.  Anticoagulation monitoring during extracorporeal membrane oxygenation: is anti-factor Xa assay (heparin level) a better test?*. , 2014, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[11]  T. Lange,et al.  Thromboelastography in patients with severe sepsis: a prospective cohort study , 2014, Intensive Care Medicine.

[12]  P. Pronovost,et al.  Variability in Anticoagulation Management of Patients on Extracorporeal Membrane Oxygenation: An International Survey* , 2013, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[13]  V. Morell,et al.  Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation , 2012, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[14]  T. Vondracek,et al.  Antifactor Xa Levels versus Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin , 2012, Pharmacotherapy.

[15]  T. Baglin,et al.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[16]  M. Ranucci,et al.  Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation , 2011, Critical care.

[17]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[18]  C. Schlensak,et al.  Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS) , 2011, Intensive Care Medicine.

[19]  L. Shekerdemian,et al.  Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life support. , 2010, Thrombosis research.

[20]  J. Nielsen,et al.  Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study , 2009, Thrombosis journal.

[21]  W. Oliver.  Anticoagulation and Coagulation Management for ECMO , 2009, Seminars in cardiothoracic and vascular anesthesia.

[22]  J. Hirsh,et al.  Monitoring unfractionated heparin with the aPTT: Time for a fresh look , 2006, Thrombosis and Haemostasis.

[23]  S. Opal,et al.  Coagulation abnormalities in critically ill patients , 2006, Critical care.

[24]  D. Kavner,et al.  Monitoring heparin therapy with thromboelastography and activated partial thromboplastin time , 1980, World Journal of Surgery.

[25]  B. M. Cohen,et al.  Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography®: critical roles of fibrinogen and factors II, VII, X and XII , 2005, Acta anaesthesiologica Scandinavica.

[26]  H. Hartert,et al.  Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren , 1948, Klinische Wochenschrift.

[27]  B. Spiess,et al.  Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies , 2004, Journal of Clinical Monitoring.

[28]  F. Colardyn,et al.  The use of the activated clotting time for monitoring heparin therapy in critically ill patients , 2003, Intensive Care Medicine.

[29]  S. Haynes,et al.  Coagulation factor activity during neonatal extra-corporeal membrane oxygenation , 2001, Intensive Care Medicine.

[30]  J. Hirsh,et al.  The binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cells. , 1999, Thrombosis research.

[31]  J. Hirsh,et al.  Induction of the Acute-Phase Reaction Increases Heparin-Binding Proteins in Plasma , 1997 .

[32]  M. Riccabona,et al.  Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. , 1996, The Journal of pediatrics.

[33]  J. Hirsh,et al.  Induction of the acute-phase reaction increases heparin-binding proteins in plasma. , 1994, Arteriosclerosis, thrombosis, and vascular biology.

[34]  R. McCarthy,et al.  Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. , 1994, Journal of cardiothoracic and vascular anesthesia.

[35]  M. Katakura,et al.  Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis. , 1990, Artificial organs.

[36]  J H Lewis,et al.  Intraoperative Changes in Blood Coagulation and Thrombelastographic Monitoring in Liver Transplantation , 1985, Anesthesia and analgesia.

[37]  K. Brinkhous,et al.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. , 1953, The Journal of laboratory and clinical medicine.